Home /Biblio

Biblio

Found 401 results
Author Keyword Title Type [ Year(Desc)]
2003
J. B. Trimbos, Parmar, M. K. B., Vergote, I. B., Guthrie, D., Bolis, G., Colombo, N., Vermorken, J. B., Torri, V., Mangioni, C., Pecorelli, S., Lissoni, A., Swart, A. Marie, Neoplasm, I. Collaborat, Research, E. Organisati, and Neoplasm, Tof Cancer, “International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma”, J Natl Cancer Inst, vol. 95, pp. 105-12, 2003.
M. J. Piccart, Floquet, A., Scarfone, G., Willemse, P. H., Emerich, J., Vergote, I. B., Giurgea, L., Coens, C., Awada, A., and Vermorken, J. B., “Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy”, Int J Gynecol Cancer, vol. 13 Suppl 2, pp. 196-203, 2003.
M. J. Piccart, Bertelsen, K., Stuart, G. C. E., Cassidy, J., Mangioni, C., Simonsen, E., James, K., Kaye, S. B., Vergote, I. B., Blom, R., Grimshaw, R., Atkinson, R. J., Swenerton, K. D., Tropé, C. G., Nardi, M., Kaern, J., Tumolo, S., Timmers, P., Roy, J. - A., Lhoas, F., Lidvall, B., Bacon, M., Birt, A., Andersen, J. E., Zee, B., Paul, J., Pecorelli, S., Baron, B., and McGuire, W. P., “Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer”, Int J Gynecol Cancer, vol. 13 Suppl 2, pp. 144-8, 2003.
M. J. Piccart, Bertelsen, K., Stuart, G. C. E., Cassidy, J., Mangioni, C., Simonsen, E., James, K., Kaye, S. B., Vergote, I. B., Blom, R., Grimshaw, R., Atkinson, R. J., Swenerton, K. D., Tropé, C. G., Nardi, M., Kaern, J., Tumolo, S., Timmers, P., Roy, J. - A., Lhoas, F., Lidvall, B., Bacon, M., Birt, A., Andersen, J. E., Zee, B., Paul, J., Pecorelli, S., Baron, B., and McGuire, W. P., “Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.”, Int J Gynecol Cancer, vol. 13 Suppl 2, pp. 144-8, 2003.
M. A. Bookman, Greer, B. E., and Ozols, R. F., “Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5”, Int J Gynecol Cancer, vol. 13, pp. 735-40, 2003.
M. A. Bookman, Greer, B. E., and Ozols, R. F., “Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5.”, Int J Gynecol Cancer, vol. 13 Suppl 2, pp. 149-55, 2003.
M. K. B. Parmar, Ledermann, J. A., Colombo, N., du Bois, A., Delaloye, J. F., Kristensen, G. B., Wheeler, S., Swart, A. Marie, Qian, W., Torri, V., Floriani, I., Jayson, G. C., Lamont, A., Tropé, C. G., ,, and Collaborators, A. G. O., “Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial”, Lancet, vol. 361, pp. 2099-106, 2003.
M. K. B. Parmar, Ledermann, J. A., Colombo, N., du Bois, A., Delaloye, J. - F., Kristensen, G. B., Wheeler, S., Swart, A. Marie, Qian, W., Torri, V., Floriani, I., Jayson, G. C., Lamont, A., and Tropé, C. G., “Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.”, Lancet, vol. 361, no. 9375, pp. 2099-106, 2003.
M. Markman, Liu, P. Y., Wilczynski, S. P., Monk, B. J., Copeland, L., Alvarez, R. D., Jiang, C., Alberts, D. S., Group, S. Oncology, and Group, G. Oncology, “Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial”, J Clin Oncol, vol. 21, pp. 2460-5, 2003.
R. F. Ozols, Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D. L., Burger, R. A., Mannel, R., DeGeest, K., Hartenbach, E. M., Baergen, R., and Group, G. Oncology, “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study”, J Clin Oncol, vol. 21, pp. 3194-200, 2003.
A. du Bois, Luck, H. J., Meier, W., Adams, H. P., Möbus, V., Costa, S., Bauknecht, T., Richter, B., Warm, M., Schröder, W., Olbricht, S., Nitz, U., Jackisch, C., Emons, G., Wagner, U., Kuhn, W., Pfisterer, J., and Group, A. Gynakologi, “A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer”, J Natl Cancer Inst, vol. 95, pp. 1320-9, 2003.
G. J. S. Rustin, “Use of CA-125 to assess response to new agents in ovarian cancer trials”, J Clin Oncol, vol. 21, p. 187s-193s, 2003.
G. J. S. Rustin, “Use of CA-125 to assess response to new agents in ovarian cancer trials.”, J Clin Oncol, vol. 21, no. 10 Suppl, p. 187s-193s, 2003.
2004
L. Butler, Bacon, M., Carey, M. S., Zee, B., Tu, D., and Bezjak, A., “Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial.”, J Clin Oncol, vol. 22, no. 12, pp. 2461-8, 2004.
B. Gronlund, Hansen, H. H., Hogdall, C., Hogdall, E. V., and Engelholm, S. A., “Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?”, Br J Cancer, vol. 90, pp. 377-82, 2004.
J. Pfisterer, du Bois, A., Wagner, U., Quaas, J., Blohmer, J. - U., Wallwiener, D., Hilpert, F., and Group, A. Gynakologi, “Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group”, Gynecol Oncol, vol. 92, pp. 949-56, 2004.
S. Camilleri-Broet, Hardy-Bessard, A. C., Le Tourneau, A., Paraiso, D., Levrel, O., Leduc, B., Bain, S., Orfeuvre, H., Audouin, J., Pujade-Lauraine, E., and Group, G. I. N. E. C. O., “HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group”, Ann Oncol, vol. 15, pp. 104-12, 2004.
C. Elie, Geay, J. - F., Morcos, M., Le Tourneau, A., Girre, V., Broet, P., Marmey, B., Chauvenet, L., Audouin, J., Pujade-Lauraine, E., Camilleri-Broet, S., and Group, G. I. N. E. C. O., “Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group)”, Br J Cancer, vol. 91, pp. 470-5, 2004.
S. Pignata and Vermorken, J. B., “Ovarian cancer in the elderly.”, Crit Rev Oncol Hematol, vol. 49, no. 1, pp. 77-86, 2004.
P. J. Eifel, Winter, K., Morris, M., Levenback, C., Grigsby, P. W., Cooper, J., Rotman, M., Gershenson, D., and Mutch, D. G., “Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01”, J Clin Oncol, vol. 22, pp. 872-80, 2004.
P. A. Vasey, Jayson, G. C., Gordon, A., Gabra, H., Coleman, R. L., Atkinson, R. J., Parkin, D., Paul, J., Hay, A., Kaye, S. B., and Group, S. Gynaecolog, “Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma”, J Natl Cancer Inst, vol. 96, pp. 1682-91, 2004.
D. H. Moore, Blessing, J. A., McQuellon, R. P., Thaler, H. T., Cella, D., Benda, J., Miller, D. S., Olt, G., King, S., Boggess, J. F., and Rocereto, T. F., “Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study”, J Clin Oncol, vol. 22, pp. 3113-9, 2004.
G. F. Fleming, Brunetto, V. L., Cella, D., Look, K. Y., Reid, G. C., Munkarah, A. R., Kline, R., Burger, R. A., Goodman, A., and Burks, R. T., “Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study”, J Clin Oncol, vol. 22, pp. 2159-66, 2004.
H. M. Keys, Roberts, J. A., Brunetto, V. L., Zaino, R. J., Spirtos, N. M., Bloss, J. D., Pearlman, A., Maiman, M. A., Bell, J. G., and Group, G. Oncology, “A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study”, Gynecol Oncol, vol. 92, pp. 744-51, 2004.
A. Bezjak, Tu, D., Bacon, M., Osoba, D., Zee, B., Stuart, G. C. E., Roy, J. - A., Piccart, M. J., and Eisenhauer, E., “Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.”, J Clin Oncol, vol. 22, no. 22, pp. 4595-603, 2004.

Pages